Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 5/20 | 0.51 |
| ▸ | G6PD | P11413 | 4/20 | 0.43 |
| ▸ | M6PR | P20645 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25499079 | 0.89 | IGF2R (0.64) | IGF2RG6PDM6PRCA1CA2 | |
| SCHEMBL1786879 | 0.89 | IGF2R (0.64) | IGF2RG6PDM6PRCA1CA2 | |
| SCHEMBL21711050 | 0.89 | IGF2R (0.64) | IGF2RG6PDM6PRCA1CA2 | |
| SCHEMBL25083591 | 0.83 | IGF2R (0.48) | IGF2RCA1CA2CA9 | |
| SCHEMBL10291466 | 0.82 | IGF2R (0.46) | IGF2RG6PDM6PRCA1CA2 | |
| SCHEMBL25084290 | 0.80 | IGF2R (0.42) | IGF2R | |
| SCHEMBL25083634 | 0.80 | IGF2R (0.42) | IGF2R | |
| Phosphoric Acid SCHEMBL28285580 | 0.78 | LGALS8 (0.51) | IGF2RG6PD | |
| SCHEMBL31103577 | 0.78 | TYR (0.46) | IGF2R | |
| SCHEMBL25670581 | 0.75 | G6PD (0.46) | IGF2RG6PDCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | IGF2R 3/4885G6PD 362/4885M6PR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.